Normative Datasets for Assessments Planned for Mild Traumatic Brain Injury (NORMAL)
NCT ID: NCT01925963
Last Updated: 2018-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
83 participants
OBSERVATIONAL
2014-01-10
2016-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants in this study will undergo numerous tests to assess physical, mental, and intellectual health and how they might change over time. Participants will wear heart and activity monitors, undergo brain imaging, provide blood and urine for laboratory testing, and have vision, hearing, balance, and muscle function tests. They will also complete a number of questionnaires and interviews. This battery of tests will be repeated twice more over the course of 6 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury
NCT01132937
MindRhythm Detection of Concussion and Recovery Study
NCT07190963
Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury
NCT01020318
Warfighter Head Injury Study
NCT00754169
Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion
NCT01535339
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A secondary purpose of this study is to compare normative values to results from randomized exploratory studies of HBO2 vs. sham control in participants with persistent post-concussive symptoms. Also, investigators will examine relationships between outcome measures from normal participants (with respect to clinical equivalence, participant burden, and risk) and compare to associations observed in other studies.
In this study, normal, healthy, non-brain injured civilians and military participants (active or inactive) will undergo a battery of outcome assessments at defined test intervals to replicate the assessment battery used in a program of studies investigating the safety of HBO2 in patients with post-concussive symptoms following mild traumatic brain injury (TBI).
The planned comprehensive assessments will obtain robust neuropsychological, physiological, and neuroimaging data. Other evaluations will include laboratory testing and evaluations of the auditory, vestibular, and visual systems. Neuroimaging (magnetic resonance imaging and computed tomography angiography) will be assessed in participants at baseline and 6 months. Neurological function and electroencephalography (EEG) will be assessed at baseline only. All other in-person outcome measures will be assessed in participants at baseline, at 13 weeks, and 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal cohort
Normal, healthy adults without history of brain injury
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men 18-65 years old and women 18-35 years old at the time of enrollment.
* Able to speak and read English, as primary language.
* Agrees to, and appears able to participate in all outcome assessments.
* Agrees to provide blood samples for laboratory tests and specimen banking.
* Demonstrates the ability to offer informed consent and signs the study informed consent document.
* No known brain imaging abnormalities.
* Known history of full term non-complicated birth.
* Estimated glomerular filtration rate (eGFR) \>90.
Exclusion Criteria
* Pregnant Women.
* Minors.
* Civilian participants with planned leave conflicting with study visits or relocation within 6 months of study enrollment, and unwilling or unable to return for follow up.
* Active duty participants with planned leave or deployment conflicting with assessment intervals.
* Any lifetime history of brain injury.
* Diagnosis of, or a persistent history of, or symptoms of a neurological disorder (e.g., tinnitus, vertigo, chronic fatigue, numbness, tingling, chronic migraine, fibromyalgia, multiple sclerosis).
* Active therapy for affective disorders, behavioral disorders, or psychological disorders.
* Diagnosis of diabetes mellitus
* Current complaints of brain injury symptoms such as cognitive or affective problems.
* Diagnosis of recurrent migraine or cluster headaches that are under medical management.
* Headaches that occur more than two times per week.
* Recurrent dizziness that requires medical management.
* Dizziness more than two times per week.
* History of theater or war zone activity that placed the participant within a combat zone environment.
* Diagnosis of PTSD or sub-clinical post-traumatic symptoms.
* Known neuroimaging abnormalities.
* Use of daily prescription drugs that could impact a normal outcome (e.g., beta blockers, antidepressants), with the following exceptions:
* Participants who are 45 or more years old may be taking statins or ACE inhibitors.
* Oral or injectable contraceptives are permitted
* Participants \<45 years old who are taking any daily prescriptions (exception - oral or injectable contraceptives)
* Known atrial septal defect.
* History of hydrocephalus/microcephaly/macrocephaly.
* History of developmental delay or learning disorder as a child.
* Women who are breastfeeding.
* Women of childbearing potential who do not agree to practice an acceptable form of birth control during the study period.
* Those who are unable to participate fully in outcome assessments unless enrollment is reviewed and approved (in writing) by the Study Director.
* Binocular vision not correctable to 20/50.
* Deafness in both ears defined as 90 decibel hearing loss or greater through speech frequencies.
* Anxiety or claustrophobia precluding participation in neuroimaging or vestibular procedures.
* History of therapeutic ionizing radiation to the head.
* Foreign material in head that would interfere with brain imaging.
* Foreign material within the individual that poses risk from MRI.
* History of illicit drug use, except remote, non-habitual use of marijuana.
* History in the last year, of alcohol abuse.
* Current positive urine test for an illicit substance(s).
* Active or prior malignancy except basal cell carcinoma within the last 5 years.
* Unable to abstain from caffeine or tobacco products for at least a 2-hour interval.
* Concurrent enrollment in any other research trial.
* Unable or unwilling to cease participation in sports or activities in which head injury is likely (e.g., mixed martial arts, boxing) during the study period.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
U.S. Army Medical Research and Development Command
FED
The Emmes Company, LLC
INDUSTRY
Intermountain Health Care, Inc.
OTHER
Evans Army Community Hospital
OTHER
Lindell Weaver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lindell Weaver
Study Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert C Price, MD
Role: PRINCIPAL_INVESTIGATOR
Evans Army Community Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Outcomes Assessment Center
Colorado Springs, Colorado, United States
Evans Army Community Hospital
Colorado Springs, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weaver LK, Cifu D, Hart B, Wolf G, Miller S. Hyperbaric oxygen for post-concussion syndrome: design of Department of Defense clinical trials. Undersea Hyperb Med. 2012 Jul-Aug;39(4):807-14.
Wetzel PA, Lindblad AS, Mulatya C, Kannan MA, Villmar Z, Gitchel GT, Weaver LK. Eye tracker outcomes in a randomized trial of 40 sessions of hyperbaric oxygen or sham in participants with persistent post concussive symptoms. Undersea Hyperb Med. 2019 BIMA Special Edition No. Feb;46(3):299-311.
Meehan A, Lewandowski A, Deru K, Hebert D, Weaver LK. Reference ranges and stability of auditory and vestibular measures in a comprehensive assessment battery for traumatic brain injury. Undersea Hyperb Med. 2019 BIMA Special Edition No. Feb;46(3):227-241.
Weaver LK, Wilson SH, Lindblad AS, Churchill S, Deru K, Price R, Williams CS, Orrison WW, Patel JB, Walker JM, Meehan A, Mirow S; NORMAL Study Team. Comprehensive Evaluation of Healthy Volunteers Using Multi-Modality Brain Injury Assessments: An Exploratory, Observational Study. Front Neurol. 2018 Dec 17;9:1030. doi: 10.3389/fneur.2018.01030. eCollection 2018.
Walker JM, Mulatya C, Hebert D, Wilson SH, Lindblad AS, Weaver LK. Sleep assessment in a randomized trial of hyperbaric oxygen in U.S. service members with post concussive mild traumatic brain injury compared to normal controls. Sleep Med. 2018 Nov;51:66-79. doi: 10.1016/j.sleep.2018.06.006. Epub 2018 Jun 30.
Wetzel PA, Lindblad AS, Raizada H, James N, Mulatya C, Kannan MA, Villamar Z, Gitchel GT, Weaver LK. Eye Tracking Results in Postconcussive Syndrome Versus Normative Participants. Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4011-4019. doi: 10.1167/iovs.18-23815.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-11-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.